Catalase watches ClinicalTrials.gov for the quiet edits that move biotech stocks — a status flip, a moved endpoint, a shortened timeline — and turns them into a plain-language alert before the market catches up.
By the time a change is visible on a headline, it's already priced in. By the time it hits a registry page, it doesn't have to be.
// hash-gated scanning, not guessworkCatalase runs the same pipeline on every ticker you track, every day the registry updates.
You point Catalase at a ticker. It resolves the company and links its active Phase 2/3 trials on the registry.
Every scan is hashed against the last known state of status, endpoints, and completion dates — no LLM call unless something actually moved.
A real shift gets passed to the AI layer, which explains what changed and why it's relevant — in plain English, not protocol jargon.
You get one line, under 140 characters, on the channel you picked. Readable in the time it takes to glance at your phone.
A real, publicly logged status change on a Pfizer trial record — the kind of edit that's easy to miss and expensive to miss.
$PFE Shift: Trial reopened enrollment (Active→Recruiting). Impact: Signals renewed confidence in protocol, near-term catalyst risk rises.
Catalase isn't trying to cover every biotech in existence or tell you what to trade. It's narrow, fast, and quiet until something real happens.
Protocol fields are fingerprinted and compared locally. The AI layer only runs on a genuine mismatch, so you're not paying — or waiting — for noise.
No endpoint jargon, no raw registry text. Every alert is one sentence: what changed, and why it matters to the stock.
From registry update to notification, the whole pipeline is built to finish before most traders have refreshed the page twice.
Send alerts to SMS, Telegram, or Discord — wherever you're actually going to see them first.
Catalase translates registry data. It never tells you what to buy or sell — the decision, and the judgment, stay yours.
Every alert attempt is logged with its destination and outcome, so nothing gets silently dropped or duplicated.
Three tiers, all built on the same detection pipeline. No tier gets a diluted version of the signal — only more of it.
No. Giving investment advice is explicitly out of scope. Catalase is a data translation layer — it monitors structural changes to trial design and timelines and explains what changed and why it's technically relevant, in plain language. The trade is always your call.
Every scan is compared against a local hash of the fields that actually matter — status, primary endpoints, completion dates. The AI layer only runs when that hash changes, so you only hear about it when something real happened.
Every dispatch attempt is logged with its destination and outcome. Failed sends are retried automatically, and Catalase checks for duplicates before it ever sends the same alert twice.
Any company with active Phase 2 or Phase 3 trials registered on ClinicalTrials.gov. Catalase isn't trying to cover every biotech in existence — it's built to watch the tickers you actually hold.
Early access rolls out to mid-cap and small-cap oncology and neurology names first.
Catalase provides informational alerts only and does not constitute investment advice.